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Background: Th2-promoting cytokine IL-25 might contribute to bronchial mucosal vascular remodelling in asthma
through its receptor expressed by vascular endothelial and vascular smooth muscle cells.
Methods: By utilising a newly established chronic asthma murine model induced by direct exposure of the airways
to IL-25 alone, we examined effects of IL-25 on angiogenesis, vascular remodelling and expression of angiogenic
factors, compared changes with those in a “classical” ovalbumin (OVA)-induced murine asthma model. IL-25 and
OVA were intranasally instilled into the airways of BALB/c mice for up to 55 days. Airways vessels and angiogenic
factors, including Von Willebrand Factor (vWF), amphiregulin, angiogenin, endothelin-1, transcription factor ERG,
basic fibroblast growth factor (bFGF), epidermal growth factor (EGF), insulin-like growth factor (IGF-1) and vascular
endothelial growth factor (VEGF) in lung sections, homogenates and BAL fluid were detected and quantified by
immunostaining or enzyme linked immunosorbent assay (ELISA). An in house assay was also utilised to compare
the effects of IL-25 and other Th2-cytokines on angiogenesis by human vascular endothelial cells.
Results: Repetitive intranasal challenge with IL-25 alone or OVA alone in OVA-presensitised animals significantly
increased peribronchial vWF + vessels in the murine airways, which was associated with remarkably elevated
expression of amphiregulin, angiogenin, endothelin-1, bFGF, EGF, IGF-1, VEGF and ERG. IL-25, but not Th-2-cytokines
induced human angiogenesis in vitro.
Conclusions: The data suggest that chronic exposure of murine airways to IL-25 alone is able to reproduce a local
angiogenic milieu. Thus, blocking IL-25 may attenuate vascular remodelling and improve outcomes in asthma patients.
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Asthma is a chronic inflammatory disorder of the airways
which is associated with airways hyperresponsiveness that
leads to recurrent episodes of wheezing and breathlessness
[1]. The pathophysiology of asthma has been intensively
investigated. Nowadays, it is well accepted that in addition
to inflammation, airways remodelling is also a hallmark
feature of asthma which has been implicated in regulating
disease severity and control [2-4]. Airways remodelling* Correspondence: wy_robin@ccmu.edu.cn
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unless otherwise stated.refers to structural changes including loss of epithelial in-
tegrity, thickening of the subepithelial basement mem-
brane caused by fibrosis, goblet cell metaplasia and
submucosal gland enlargement, increased airway smooth
muscle mass, increased airways vascularity and vascular re-
modelling [2-4]. Although the notion that airways remodel-
ling is one of the key features of asthma is well established,
the underlying mechanisms have not been fully clarified. It
is now hypothesised that inflammation and vascular re-
modelling in asthma are partially interdependent, reflecting
a dysregulated wound healing process resulting in extracel-
lular matrix deposition and angiogenesis [5].
Angiogenesis of bronchial mucosal vessels may be ob-
served in response to a wide variety of stimuli, includingis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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the formation of new vessels by sprouting from pre-
existing vessels and/or lengthening and enlargement of
existing vessels. Angiogenesis is a complex multiphase
process, potentially involving a great number of growth
factors, cytokines, chemokines, enzymes and other fac-
tors [4,6]. These are produced by resident stromal or
inflammatory cells, creating a “vascular remodelling mi-
lieu”. Notwithstanding that vascular endothelial growth
factor (VEGF) is considered to be a key mediator in this
process, the specific roles of other molecules remain to
be defined [6].
IL-25 (IL-17E), a distant member of the IL-17 family has
been demonstrated to induce Th2-type immune re-
sponses, indicating that it may contribute to the pathogen-
esis of asthma and thereby this “vascular remodelling
milieu” [7]. In mice, overexpression or exogenous admin-
istration of IL-25 produces an asthma-like inflammatory
response, including increased serum IgE production,
blood eosinophilia and lung eosinophilic infiltrates, epi-
thelial cell hyperplasia/hypertrophy, increased mucusFigure 1 IL-25 increased airways vWF expression. A: Representative ph
lung sections from saline (NS)-, OVA- and IL-25-challenged mice at various
analysis of vWF+ blood vessels per unit area of lung sections. Data were co
mean ± SEM (n = 5 in each group of mice at each time point).*p < 0.05.secretion and airways hyperreactivity [8-11]. Conversely,
blockade of IL-25 remarkably reduced Th2 cytokine
production and airways inflammation [7,12], and in
addition ameliorated airways remodelling changes in-
cluding peribronchial collagen deposition and smooth
muscle hyperplasia, with corresponding reduction of
hyperreactivity [12].
Our recent previous data further underline the ability
of IL-25 to effect airways inflammation and fibrosis
in vivo. Firstly, we detected elevated expression of IL-25
and its receptor in the human asthmatic bronchial mu-
cosa at baseline and following allergen challenge [13].
Secondly, we showed that chronic intranasal instillation
of IL-25 into murine airways is able to induce acute
and chronic inflammatory responses reminiscent of hu-
man asthma [14]. Thirdly, we showed that IL-25, by
binding to its IL-25R/IL-17RB, but not its IL-17RA
receptor enhanced human lung vascular endothelial
cell proliferation and angiogenesis in vitro by increasing
the expression by these cells of basic fibroblast growth
factor (bFGF) and VEGF and VEGF receptors [15,16].otomicrographs of von Willebrand factor (vWF) immunoreactivity in
time points as indicated (original magnification x20). B: Quantitative
llected from 3 independent experiments and are expressed as the
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the full range of potential effects of IL-25 in promoting
a “vascular remodelling milieu” in the setting of asth-
matic inflammation in vivo. In particular, angiogenic and
growth factors such as epidermal growth factor (EGF),
ETS-related gene (ERG), insulin-like growth factor 1
(IGF-1), amphiregulin, angiogenin and endothelin-1, to-
gether with transforming growth factor-β1 (TGF-β1),
VEGF and bFGF have been suggested to have potential to
participate in this “remodelling milieu”[4].
Consequently we set out to extend our previous stud-
ies to examine the direct effects of IL-25 alone on the
production of these mediators in the airways in vivo in
our murine model of chronic asthma. In this model, we
compared in parallel the effects of direct intranasal in-
stillation of IL-25 with those of intranasal OVA adminis-
tered to mice pre-sensitised to mount an IgE response
to OVA by intraperitoneal sensitization (a “classical”
murine asthma model). Finally, we compared the direct
effects of IL-25 with those of IL-4, IL-5 and IL-13 in
promoting angiogenesis in a human in vitro model.Figure 2 IL-25 increased airways ERG expression. A: Representative pho
sections from saline (NS)-, OVA- and IL-25-challenged mice at various time
of ERG immunoreactivity. The data were collected from 3 independent exp
at each time point). *p < 0.05.Methods
Animals
Female BALB/c mice (8–10 wk old) were purchased
from Vital River Laboratories (Beijing, China) and main-
tained in a pathogen free mouse facility located in the
Department of Laboratory Animal Sciences, Capital
Medical University, Beijing, China. They were kept in
12 h light and 12 h dark with free access to food and
water. All experiments were approved by the Institu-
tional Animal Care and Use Committee (IACUC).
Allergen- and IL-25 intranasal instillation protocol
Mice were divided into 3 groups, including a group seri-
ally challenged with OVA (a “classical” allergen-induced
asthma model) [14,17], a group challenged with saline
as a negative control and a group serially challenged
with IL-25. Briefly, OVA-challenged group were first
sensitized by intraperitoneal injection of OVA (Sigma-
Aldrich, Beijing, China, 100 μg emulsionised in Al[OH]
3/dose) on days 0 and 12. Then 50 μg of OVA (OVA50)
in 50 μL saline/dose were further administered to thesetomicrographs of ETS-related gene (ERG) immunoreactivity in lung
points as indicated (original magnification x20). B: Quantitative analysis
eriments and are expressed as the mean ± SEM (n = 5 in each group
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challenged group were not sensitized to OVA on days 0
and 12, but suffered daily nasal instillation with recom-
binant mouse IL-25 (mIL-25, R&D Systems, 2 μg in 50
uL saline) from days 18 to 23 [14,18]. Subsequently,
these mice were further challenged intranasally either
with OVA (OVA50 group) or with IL-25 (IL-25 group)
every 2 days for a further 30 days. 5 mice in each group
were observed for a further 17 days after stopping the
challenges. Saline negative group was intraperitoneally
injected with the same amount of Al[OH]3 on days 0
and 12, then nasally administered with saline at time
points corresponding to those in the other groups.Bronchoalveolar lavage fluid collection and preparation
of lung tissue homogenates
Bronchoalveolar lavage fluid (BALF) was collected from
mice immediately following euthanasia as previously de-
scribed [14]. Supernatants were stored at - 80°C until used.
Right lung tissue (100 mg) was homogenized in 2 mL
PBS containing 1% Triton-X100 and a protease inhibitor
cocktail tablet (Roche Diagnostics GmbH, Mannheim,
Germany). Debris was removed by centrifugation and theFigure 3 IL-25 potentiated airways VEGF and bFGF expression. Conce
endothelial growth factor (VEGF, C and D) in bronchoalveolar lavage fluid (
challenged mice at various time points as indicated. The data were collecte
SEM (n = 5 in each group at each time point). *p < 0.05.supernatants collected and stored at - 80°C until used for
measurement of analytes.Analysis of VEGF and bFGF
VEGF and bFGF concentrations in BALF and lung homog-
enates were measured using commercial ELISA kits
(eBioscience, San Diego, CA). In brief, 100 μl of capture
antibody were added to each plate well overnight at 4°C.
After washing 5 times, 100 μl of acidified BALF or lung
homogenate were added to the plate wells which were then
incubated for 2 h at room temperature (RT). After 5
washes, 100 μl of detection antibody were added to each
well and the plates incubated for a further 1 hr at 37°C.
After washing, 100 μl of avidin-HRP labelled antibody were
added and the plates incubated for 30 min at RT. Plates
were washed again 5 times and 100 μl of substrate solution
added to each well for incubation at RT in the dark. After
colour development, 50 μl of stop solution were added to
each well. Absorbance was measured at 450 nm using a
GloMAc-Multi Detection System (e7801, Shanghai Pro-
mega Biological Products, Ltd, China). Concentrations of
VEGF and bFGF in BALF and lung homogenates were de-
termined by interpolation from the standard curve.ntrations of basic fibroblast growth factor (bFGF, A and B) and vascular
BALF) and lung tissue homogenates from saline (NS)-, OVA- and IL-25-
d from 3 independent experiments and are expressed as the mean ±
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Immunohistochemistry was used to detect bronchial
vascular biomarkers. The primary monoclonal antibodies
against mouse transcription factor (ERG, 1:80), epider-
mal growth factor (EGF, 1:100), insulin-like growth fac-
tor (IGF-1, 1:400), endothelin-1 (1:600), angiogenin
(1:400) and amphiregulin (1:500) were purchased from
Abcam (Hong Kong, China). The primary monoclonal
antibody against mouse Von Willebrand factor (vWF,
1:50) was purchased from CHEMICON International,
Inc. MA 01730. The PAP (peroxidase anti-peroxidase)
technique was used as previously described [13-15].
Positively staining cells were detected using the glucose
oxidase-DAB-nickel method [19]. At least 8 random
high-power fields (200 × total magnification) of each
mice in the 3 groups should be independently analysed
by 2 observers in a blinded fashion on a Leica DM6000B
microscope (Leica, Wetzlar, Germany) connected with a
Leica Application Suite Version 3.6. The data were
expressed as percentages of positive stained areas per
unit area of entire lung sections.Figure 4 IL-25 induced airways EGF expression. A: Representative phot
lung sections from saline (NS)-, OVA- and IL-25-challenged mice at various
analysis of EGF immunoreactivity. The data were collected from 3 independ
group at each time point). *p < 0.05.In vitro angiogenesis assay
It is believed that Th2-type cytokines such as IL-4, IL-5
and IL-13 play a significant role in airways remodelling
in asthma. To further investigate whether these cyto-
kines also have effects on angiogenesis, we used a well
established in vitro angiogenesis assay (AngioKit; TCS
CellWorks, Buckingham, UK) [15,16], which is based on
co-culture of HUVEC over a monolayer of irradiated fi-
broblasts. Briefly, cultures were incubated at 37°C in a
humidified atmosphere with 5% CO2. Culture medium
with recombinant human IL-4, IL-5, IL-13 and IL-25
(10 ng/ml, R&D Systems, Abingdon, UK) [15,16] was
replenished on days 4, 7, and 9. Culture medium alone and
recombinant human VEGF-A (R&D Systems, 10 ng/ml)
[15,16] served as negative and positive assay controls,
respectively. On day 11 cultured cells were fixed and
vascular structures visualized by labelling with mouse
anti-CD31 according to the manufacturer’s instructions.
Multiple photomicrographs (×4 objective) (4 separate
fields per well) were taken at clock points 12, 3, 6 and 9,
and angiogenesis in each field of view quantified usingomicrographs of epidermal growth factor (EGF) immunoreactivity in
time points as indicated (original magnification x20). B: Quantitative
ent experiments and are expressed as the mean ± SEM (n = 5 in each
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scribed previously [15,16]. The analysis software segmented
the images using a grey level threshold tool to select CD31-
labelled cells. The resultant binary images were skeletonized
and branch points removed to determine the total lengths
of individual tubules. Branch points were counted and the
total area of CD31 labelling determined from the original
binary images, permitting overall numbers of vascular junc-
tions, tubules, and tubule length to be determined.
Statistical analysis
The results were analyzed using InStat 2.01 software
(GraphPad, San Diego, CA, USA). Differences between ex-
perimental groups were analyzed using 2-way parametric
ANOVA followed by a Bonferroni post test or the Student’s
unpaired t test. Data are presented as the mean ± SEM. For
all tests, p values less than 0.05 were considered significant.
Results
IL-25 increased airways vascularity
Immunoanalysis showed that IL-25, as compared with
saline challenge induced marked airways angiogenesis asFigure 5 IL-25 induced airways IGF-1 expression. A: Representative pho
in lung sections from saline (NS)-, OVA- and IL-25-challenged mice at vario
analysis of IGF-1 immunoreactivity. The data were collected from 3 indepen
group at each time point). *p < 0.05.indicated by significantly elevated numbers of peri-
bronchial, vWF+ immunoreactive blood vessels from day
36 and persisting until the end of the experiment (day
70) (Figure 1). Similarly, OVA challenged animals also
showed elevated vWF+ immunoreactive vessels from days
36 to 55 which however declined by day 70 (Figure 1).
Correspondingly, IL-25 challenge also significantly increased
the expression of global airways ERG immununoreactivity
from day 36 until day 70 (Figure 2). OVA challenge
similarly increased ERG expression although this was
evident slightly earlier from day 24 until the end of the
experiment (Figure 2).
IL-25 potentiated airways parenchymal and luminal VEGF
and bFGF expression
IL-25, as compared with saline challenge of the murine
airways induced significantly elevated mean concentra-
tions of bFGF, as measured by ELISA, in lung homoge-
nates from day 20 and in BALF from day 36, with
resolution in BALF by day 70 (Figure 3). Mean VEGF
concentrations were also significantly elevated in lung
homogenates from day 24 and BALF from day 36 untiltomicrographs of insulin-like growth factor 1 (IGF-1) immunoreactivity
us time points as indicated (original magnification x20). B: Quantitative
dent experiments and are expressed as the mean ± SEM (n = 5 in each
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lar changes in bFGF and VEGF concentrations in both
compartments with a similar time course (Figure 3).
IL-25 induced airways EGF and IGF-1 expression
Immunoanalysis showed that IL-25, as compared with
saline challenge of the airways significantly increased
the expression of lung and peribronchial EGF and IGF-1
immunoreactivity from day 36 until the end of the ex-
periment (Figures 4 and 5). OVA challenge produced a
similar effect which was apparent earlier (from day 20)
and more marked between days 20 and 36 in the case of
EGF (Figures 4 and 5).
IL-25 induced elevated airways endothelin-1, angiogenin
and amphiregulin expression
Immunoanalysis showed that IL-25 as compared with
saline challenge of the airways significantly increased
expression of lung and peribronchial endothelin-1,
angiogenin and amphiregulin immunoreactivity from
day 24 (endothelin-1) or day 36 until the end of theFigure 6 IL-25 induced airways endothelin-1 expression. A: Representative
from saline (NS)-, OVA- and IL-25-challenged mice at various time points as ind
immunoreactivity. The data were collected from 3 independent experiments a
time point). *p < 0.05.experiment. OVA challenge induced similar but more
marked changes which were apparent earlier (From days
20 or 24) (Figures 6, 7 and 8).
IL-25, but not IL-4, IL-5 or IL-13 induced angiogenesis
in vitro
In an in vitro angiogenesis assay, IL-25, but not IL-4,
IL-5 or IL-13, induced lengthening and branching of
microvascular tubules by HUVEC as compared with
VEGF, which was used as a positive control (Figure 9).
Discussion
Accumulating reports have firmly established angiogen-
esis and vascular remodelling as features of asthma
pathophysiology which could have an important impact
on day to day symptomatology as well as the natural his-
tory of the disease [20-22]. So far, relatively little is
known about the mechanisms of these changes. Here we
demonstrate that chronic challenge of murine airways
with IL-25 alone has the capacity to induce angiogenesis
in vivo and increase local production of a variety ofphotomicrographs of endothelin-1 immunoreactivity in lung sections
icated (original magnification x20). B: Quantitative analysis of endothelin-1
nd are expressed as the mean ± SEM (n = 5 in each group at each
Figure 7 IL-25 induced airways angiogenin expression. A: Representative photomicrographs of angiogenin immunoreactivity in lung sections
from saline (NS)-, OVA- and IL-25-challenged mice at various time points as indicated (original magnification x20). B: Quantitative analysis of
angiogenin immunoreactivity. The data were collected from 3 independent experiments and are expressed as the mean ± SEM (n = 5 in each
group at each time point). *p < 0.05.
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tion resembling that induced by “classical” murine
asthma models which require prior IgE sensitization of
the animals. The only difference was that some of the
changes were more marked and some occurred slightly
earlier with OVA, as compared with IL-25 challenge,
perhaps at least partly reflecting the release of mast cell
mediators in the airways. This does not of course imply
that the molecular mechanisms inducing these changes
are necessarily similar, but does underline the potential
pleiotropic activities of IL-25 alone. Further, we have
shown that, although a variety of Th2 cytokines as well
as IL-25 have been implicated in causing remodelling
changes in human and murine airways in asthma, only
IL-25, and not IL-4, IL-5 or IL-13 is able directly to in-
duce angiogenesis by human vascular endothelial cells.
This extends our previous data [16] and is also congru-
ent with previous study [12] showing that angiogenesis
is increased in the airways of mice sensitized to, then
challenged with house dust mite and that this can be ab-
rogated by IL-25 blockade, possibly at least partly byreduced recruitment of CXCR2 endothelial cell progeni-
tors from the bone marrow.
Vascular endothelial growth factor (VEGF) is currently
considered to be a key angiogenic factor in asthma [23],
while the expression of bFGF is also upregulated in hu-
man asthma and has been correlated with the increased
vascularity of the bronchial mucosa and lung function
[24,25]. Our data showed that both IL-25 and OVA-
challenged mice showed increased production of both me-
diators, first in the lung parenchyma and in the airways
lumen, with a time course reflecting that of elevated blood
vessel signature markers including vWF and ERG. vWF is
a common marker for evaluating angiogenesis in vivo and
ex vivo [12], while ERG is a member of the ETS (erythro-
blast transformation-specific) family of transcription fac-
tors which is selectively expressed by endothelial cells,
specific haematopoetic cells and pre-cartilage cells. It has
been shown that ERG plays an important role in blood
vessel homeostasis and angiogenesis by regulating a var-
iety of endothelial cellular functions including survival,
junctional stability and migration [26].
Figure 8 IL-25 induced airways amphiregulin expression. A: Representative photomicrographs of amphiregulin immunoreactivity in lung
sections from saline (NS)-, OVA- and IL-25-challenged mice at various time points as indicated (original magnification x20). B: Quantitative analysis
of amphiregulin immunoreactivity. The data were collected from 3 independent experiments and are expressed as the mean ± SEM (n = 5 in each
group at each time point). *p < 0.05.
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reflects a balance between the production of endogenous
angiogenic activators and inhibitors. When the balance
is perturbed because of over-production of angiogenic
factors and/or down-regulation of inhibitors, a pro-
angiogenic niche ensues and aberrant vascularisation
occurs [2-4]. Aside from VEGF and FGF, which are
heparin binding growth factors, several other pro-
angiogenic mediators have been implicated in regulating
neovascularisation in airways. Circulating concentra-
tions of insulin-like growth factor (IGF-I) have been
linked with airways vascular remodelling in patients
with chronic airways disease [27]. Inhibition of epider-
mal growth factor (EGF) receptor signalling ameliorated
airways hyperreactivity and remodelling in a murine
model of chronic asthma [28]. Amphiregulin, a member
of the EGF family and another ligand of the EGF recep-
tor, has been shown to promote proliferation of airways
epithelial and smooth muscle cells and mucin gene expres-
sion [29]. Neutralization of amphiregulin also prevented
cultured endothelial cells from forming tubes [30]. Inaddition to growth factors, other pro-angiogenic mediators
such as endothelin-1 and angiogenin also contribute to ab-
errant intrapulmonary neovascularisation and remodelling
[31-33]. Endothelin-1, in addition to promoting synthesis
of ECM proteins by epithelial cells and fibroblasts, myo-
fibroblast differentiation and proliferation of mesenchy-
mal cells, also induces migration and proliferation of
vascular cells [34]. Angiogenin, first isolated from con-
ditioned medium of colonic carcinoma cell cultures, is a
potent tumour-derived angiogenic factor but also plays
a role in several non-malignant vasculoproliferative disor-
ders, and like VEGF induces vascular endothelial cell pro-
liferation, migration and tubule formation [35]. Our data
show that all of these pro-angiogenic agents have the po-
tential to be upregulated by IL-25 alone in the setting of
asthma-like inflammation of the airways in vivo, with a
time course congruent with that of angiogenesis.
Conclusions
Our data do not distinguish between direct and indirect
effects of IL-25 in causing angiogenesis, although we
Figure 9 IL-25, but not IL-4, IL-5 or IL-13 induced angiogenesis in vitro. Top panel: representative light photomicrographs (4x original
magnification) show formation of primitive vascular tubule structures by human vascular endothelial cells after 11 days of culture (top panel) with
medium (A), VEGF (10 ng/mL) (B), IL-25 (10 ng/mL) (C), IL-4 (10 ng/mL) (D), IL-5 (10 ng/mL) (E) and IL-13 (10 ng/mL) (F). Bottom panel:
computer-assisted quantification of total tubule lengths (G), numbers of branch points (H) and total numbers of tubules (I). Bars show the mean
± SEM of three separate experiments performed in duplicate. *p < 0.05. Mann–Whitney U test. *p < 0.05.
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endothelial cells to induce angiogenesis, albeit at least
partly through increasing VEGF and bFGF expression
by these cells, whereas other Th2-type cytokines (IL-4,
IL-5, IL-13), as shown in this study, do not. Angiogen-
esis likely involves many cell types including fibroblasts
and vascular smooth muscle cells [2-6]. We have fur-
ther preliminary data suggesting that IL-25 also induces
expression of VEGF and EGF fibrotic factors by human
lung fibroblasts (in preparation). We conclude that
IL-25 may be a master switch for the production of
many important pro-angiogenic mediators by a diverse
variety of airways structural cells. Targeting IL-25 may
provide a novel therapeutic approach to altering the
natural history of asthmatic inflammation and associ-
ated symptoms.Abbreviations
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